Paion

Edison Investment Research is terminating coverage on Paion. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

World’s Toughest Row 2024

About Edison

About Edison

Careers

Paion (DE: PA8)

Latest Insights

Paion — GA data enable an application for surgical use

Paion — Commercialisation of remimazolam underway

Paion — Remimazolam: Three major approvals

Paion — ByFavo – poised for autumn US launch

Sector

Financials

Paion — Progressing towards filings in US and Japan

Paion — US and Japan filings and EU Phase III on track

Paion — Remimazolam set for commercialisation in 2019

Paion — Positive data in bronchoscopy Phase III

Paion — On track for two filings by mid-2018

Paion — On track to file in US and Japan by mid-2018

Paion — Positive data in high-risk patients

Paion — Update 21 November 2016

Paion — Update 5 July 2016

Paion — Update 17 May 2016

Paion — Update 16 February 2016

Paion — Update 9 February 2016

Paion — Update 17 November 2015